InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,726.08
(
-0.21%
)
US TECH 100
19,420.00
(
-0.26%
)
Dow Jones
42,098.31
(
-0.51%
)
Brent Oil
71.93
(
0.31%
)
Bitcoin
63,354.75
(
-3.46%
)
Post# of 253255
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Hedge Starz

Send PM Follow Ignore
Followers 226
Posts 31043
Boards Moderated 0
Alias Born 02/12/2008

Hedge Starz

Re: swampboots post# 156990

Friday, 02/15/2013 10:59:10 AM

Friday, February 15, 2013 10:59:10 AM

Post# of 253255
"With $8.8 million of funding from the National Institutes of Health (NIH) and outstanding strategic development and regulatory support from Cato Research Ltd., we have successfully completed the required studies enabling Phase 2 clinical development of AV-101 for multiple large market neurological diseases and conditions. In addition, recent data from the NIH suggest that the same neural pathway modified by AV-101 may be useful for treating depression. Launching a broad strategic collaboration to advance development and commercialization of AV-101 is among our key goals in 2013."

Just showcasing the Financial Backers (NIH....NIH). Not many smallcap otcbb biotechs have what $VSTA has going. Keep it marked for more news.

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up